PMH26 USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65076-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)65076-0/fulltext
Title :
PMH26 USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65076-0&doi=10.1016/S1098-3015(10)65076-0
First page :
Section Title :
Open access? :
No
Section Order :
234